Sector revisions Takeda Pharmaceutical Company Limited

Equities

Market Closed - Japan Exchange Other stock markets 01:30:00 2026-01-23 EST			5-day change	1st Jan Change
5,116.00 ^JPY	+1.77%		+0.85%	+5.81%

01-22	Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-To-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A Content	CI
01-22	Takeda Pharmaceutical Launches Liquid Medicine for Primary Immunodeficiency in US	MT

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	ELI LILLY AND COMPANY							28
	JOHNSON & JOHNSON							24
	ABBVIE INC.							27
	ROCHE HOLDING AG							19
	ASTRAZENECA PLC							20
	NOVARTIS AG							20
	NOVO NORDISK A/S							21
	MERCK & CO., INC.							27
	AMGEN INC.							27
	GILEAD SCIENCES, INC.							26
	PFIZER INC.							24
	VERTEX PHARMACEUTICALS INCORPORATED							25
	SANOFI							22
	BRISTOL-MYERS SQUIBB COMPANY							23
	GSK PLC							19
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	BAYER AG							20
	Average							22
	Weighted average by Cap.							24